Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26840474 | 0.95 | KDM4E (0.38) | KDM4EADORA3TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL22408779 | 0.88 | TYMP (0.36) | KDM4E | |
| SCHEMBL22408780 | 0.88 | TYMP (0.36) | KDM4E | |
| SCHEMBL1408652 | 0.82 | KDM4E (0.47) | KDM4EADORA3TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL19604056 | 0.81 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1TAAR1 | |
| SCHEMBL19631499 | 0.81 | ADORA3 (0.43) | ADORA3 | |
| SCHEMBL19628261 | 0.79 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1ALDH1A1TAAR1 | |
| SCHEMBL19628246 | 0.79 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1ALDH1A1TAAR1 | |
| SCHEMBL22408784 | 0.79 | TYMP (0.37) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL22408783 | 0.79 | TYMP (0.37) | KDM4ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017157672-A1 | ACYL-PROTECTED L-LNA-GUANOSINE MONOMERS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-09-21 | — | — | WO | disclosed |